Johnson & Johnson (JNJ) Clears Its Prior Peak, Closing at $282.11
As seen on the 24/7 Wall St. homepage on November 9, 2026.
Johnson & Johnson closed at $282.11, clearing its September 3 peak by 1.32%. Gilead and AbbVie also finished higher.
Moves: Nov 9, 2026 · Alpha Vantage daily close
4 more related stocks · 1 has no US listing
Continue ReadingShow less
Johnson & Johnson closed at $282.11 on November 9, 2026, a gain of 1.32% that cleared the prior high set on September 3. Everyone who bought since that September date is now in profit, which removes a broad layer of selling pressure that builds around contested highs.
The advance has steepened in recent months, and $282.11 is the highest close in the dataset. Momentum is broadening into the breakout, a constructive setup for buyers.
Sponsored
Gilead Sciences rose 1.46% and AbbVie added 0.71% in the same session, so large-cap pharmaceutical names attracted buyers broadly. That kind of peer move points to a macro tailwind for healthcare or institutional buying of defensive, dividend-oriented stocks.
For holders, the new high clears the technical uncertainty around the prior peak and reinforces the uptrend. For anyone on the sidelines, the question is whether the run from the low $200s to $282.11 extends or pauses to consolidate.